What is BMAC (bone marrow stem cell concentrate)?
BMAC (Bone Marrow Aspirate Concentrate) is an autologous biological preparation made by taking a small amount of a patient’s own bone marrow (usually the iliac crest) and centrifuging it to concentrate cells and growth factors. Known first for joint treatment, it’s now drawing interest as an IV procedure for systemic immune modulation.
It’s often compared to PRP, but the composition differs decisively — mesenchymal stem cells (MSCs) and IL-1RA (which blocks IL-1 inflammatory signaling) are far richer in BMAC.
| Component | Main role | vs PRP |
|---|---|---|
| Mesenchymal stem cell (MSC) | Tissue regeneration, immune modulation, anti-inflammation | BMAC only |
| Hematopoietic stem cell (HSC) | Source of blood and immune cells | Much higher in BMAC |
| TGF-β, PDGF, VEGF | Tissue regeneration, angiogenesis | Both |
| IL-1RA | Blocks IL-1 inflammatory signaling | Higher in BMAC |
| BMP-2, BMP-7 | Bone and cartilage regeneration signals | BMAC only |
From musculoskeletal to systemic — expanding scope
BMAC already has substantial clinical data in knee and hip osteoarthritis and cartilage/ligament injury. A systematic review including 876 patients (2024) consistently reported pain reduction, functional gains, and improved quality of life, with some studies showing mid-term durability over PRP and hyaluronic acid.
This established local safety and efficacy has become the trust foundation for systemic-use research.
Four mechanisms with systemic infusion
Given intravenously, BMAC is thought to act as follows. 1) Immune remodeling — MSCs suppress over-activated cytokines like TNF-α and IL-1β and activate regulatory T cells (Tregs). 2) Reducing chronic low-grade inflammation — easing the ‘inflammaging’ that rises with age at a systemic level. 3) Stem cell homing — cells traveling the bloodstream home to inflamed sites and activate repair signals. 4) Paracrine effect — even without direct differentiation, releasing regenerative signals (exosomes, growth factors) to promote recovery.
Why autoimmune and menopause draw attention
Autoimmune diseases (like psoriasis) involve immune cells attacking one’s own tissue. Just as biologics block TNF-α, IL-17, and IL-23, the MSCs and IL-1RA in BMAC engage similar anti-inflammatory pathways.
| Autoimmune key pathway | BMAC’s action |
|---|---|
| TNF-α over-activation | MSC paracrine effect suppresses TNF-α secretion |
| IL-1β-mediated inflammation | IL-1RA blocks IL-1 receptor binding |
| T-cell over-response | MSCs induce regulatory T cells (Tregs) |
| Macrophage M1 polarization | MSCs promote M2 (anti-inflammatory) differentiation |
Menopause, too, isn’t just falling estrogen but a mix of ovarian aging, rising systemic inflammation, and declining marrow stem cell activity. In premature ovarian failure (Igboeli 2020), bone-marrow MSCs were reported to raise estrogen by about 150% with menopausal symptoms improving over a year.
Direct skin injection — flushing and rosacea
Beyond systemic use, injecting BMAC directly into the skin is also being tried clinically. Improvement has been reported especially in refractory facial flushing and rosacea that worsen after menopause.
The rationale: after menopause, skin vascular instability and neurogenic inflammation increase, and BMAC’s MSCs and growth factors (VEGF, TGF-β) may act to re-tune vascular signaling and suppress immune over-response. Controlled clinical data is still limited, so mechanistic plausibility and clinical observation are expanding together.
In short — between plausibility and prudence
Regenerative medicine is evolving fast. In areas where clinical practice runs ahead of data — like systemic BMAC — deep mechanistic understanding and careful judgment matter most. Being autologous, it carries no rejection and has good short-term safety, but large RCTs are still lacking. Please judge suitability through a specialist consultation.
